420 related articles for article (PubMed ID: 25222039)
21. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition.
Storandt M; Mintun MA; Head D; Morris JC
Arch Neurol; 2009 Dec; 66(12):1476-81. PubMed ID: 20008651
[TBL] [Abstract][Full Text] [Related]
22. Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults.
Guo T; Landau SM; Jagust WJ;
Neurology; 2020 Apr; 94(14):e1512-e1524. PubMed ID: 32188766
[TBL] [Abstract][Full Text] [Related]
23. The effect of amyloid β on cognitive decline is modulated by neural integrity in cognitively normal elderly.
Wirth M; Oh H; Mormino EC; Markley C; Landau SM; Jagust WJ
Alzheimers Dement; 2013 Nov; 9(6):687-698.e1. PubMed ID: 23474040
[TBL] [Abstract][Full Text] [Related]
24. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ;
Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606
[TBL] [Abstract][Full Text] [Related]
25. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
26. Hippocampal and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Alzheimer's Disease Pathology.
Chung JK; Plitman E; Nakajima S; Caravaggio F; Iwata Y; Gerretsen P; Kim J; Takeuchi H; Shinagawa S; Patel R; Chakravarty MM; Graff-Guerrero A;
J Alzheimers Dis; 2017; 58(3):747-762. PubMed ID: 28505977
[TBL] [Abstract][Full Text] [Related]
27. Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's disease.
Papp KV; Amariglio RE; Mormino EC; Hedden T; Dekhytar M; Johnson KA; Sperling RA; Rentz DM
Neuropsychologia; 2015 Jul; 73():169-75. PubMed ID: 26002757
[TBL] [Abstract][Full Text] [Related]
28. Association of β-Amyloid and Apolipoprotein E ε4 With Memory Decline in Preclinical Alzheimer Disease.
Lim YY; Kalinowski P; Pietrzak RH; Laws SM; Burnham SC; Ames D; Villemagne VL; Fowler CJ; Rainey-Smith SR; Martins RN; Rowe CC; Masters CL; Maruff PT
JAMA Neurol; 2018 Apr; 75(4):488-494. PubMed ID: 29356823
[TBL] [Abstract][Full Text] [Related]
29. Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study.
Yau WW; Tudorascu DL; McDade EM; Ikonomovic S; James JA; Minhas D; Mowrey W; Sheu LK; Snitz BE; Weissfeld L; Gianaros PJ; Aizenstein HJ; Price JC; Mathis CA; Lopez OL; Klunk WE
Lancet Neurol; 2015 Aug; 14(8):804-813. PubMed ID: 26139022
[TBL] [Abstract][Full Text] [Related]
30. Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease.
Doré V; Villemagne VL; Bourgeat P; Fripp J; Acosta O; Chetélat G; Zhou L; Martins R; Ellis KA; Masters CL; Ames D; Salvado O; Rowe CC
JAMA Neurol; 2013 Jul; 70(7):903-11. PubMed ID: 23712469
[TBL] [Abstract][Full Text] [Related]
31. The influence of demographic factors on subjective cognitive concerns and beta-amyloid.
Aghjayan SL; Buckley RF; Vannini P; Rentz DM; Jackson JD; Sperling RA; Johnson KA; Amariglio RE
Int Psychogeriatr; 2017 Apr; 29(4):645-652. PubMed ID: 27724996
[TBL] [Abstract][Full Text] [Related]
32. Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers.
Nho K; Kueider-Paisley A; Ahmad S; MahmoudianDehkordi S; Arnold M; Risacher SL; Louie G; Blach C; Baillie R; Han X; Kastenmüller G; Trojanowski JQ; Shaw LM; Weiner MW; Doraiswamy PM; van Duijn C; Saykin AJ; Kaddurah-Daouk R;
JAMA Netw Open; 2019 Jul; 2(7):e197978. PubMed ID: 31365104
[TBL] [Abstract][Full Text] [Related]
33. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
[TBL] [Abstract][Full Text] [Related]
34. Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly.
Vemuri P; Lesnick TG; Przybelski SA; Knopman DS; Preboske GM; Kantarci K; Raman MR; Machulda MM; Mielke MM; Lowe VJ; Senjem ML; Gunter JL; Rocca WA; Roberts RO; Petersen RC; Jack CR
Brain; 2015 Mar; 138(Pt 3):761-71. PubMed ID: 25595145
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.
Wang L; Benzinger TL; Su Y; Christensen J; Friedrichsen K; Aldea P; McConathy J; Cairns NJ; Fagan AM; Morris JC; Ances BM
JAMA Neurol; 2016 Sep; 73(9):1070-7. PubMed ID: 27454922
[TBL] [Abstract][Full Text] [Related]
36. Association of β-Amyloid and Vascular Risk on Longitudinal Patterns of Brain Atrophy.
Rabin JS; Pruzin J; Scott M; Yang HS; Hampton O; Hsieh S; Schultz AP; Buckley RF; Hedden T; Rentz D; Johnson KA; Sperling RA; Chhatwal JP
Neurology; 2022 Jul; 99(3):e270-e280. PubMed ID: 35473760
[TBL] [Abstract][Full Text] [Related]
37. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
[TBL] [Abstract][Full Text] [Related]
38. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.
Villemagne VL; Burnham S; Bourgeat P; Brown B; Ellis KA; Salvado O; Szoeke C; Macaulay SL; Martins R; Maruff P; Ames D; Rowe CC; Masters CL;
Lancet Neurol; 2013 Apr; 12(4):357-67. PubMed ID: 23477989
[TBL] [Abstract][Full Text] [Related]
39. Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease.
Bransby L; Lim YY; Ames D; Fowler C; Roberston J; Harrington K; Snyder PJ; Villemagne VL; Salvado O; Masters CL; Maruff P
J Clin Exp Neuropsychol; 2019 Aug; 41(6):591-600. PubMed ID: 30924399
[No Abstract] [Full Text] [Related]
40. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease.
Villemagne VL; Pike KE; Chételat G; Ellis KA; Mulligan RS; Bourgeat P; Ackermann U; Jones G; Szoeke C; Salvado O; Martins R; O'Keefe G; Mathis CA; Klunk WE; Ames D; Masters CL; Rowe CC
Ann Neurol; 2011 Jan; 69(1):181-92. PubMed ID: 21280088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
